Naglaa Shehab | Drug Discovery and Development | Editorial Board Member

Published on by Top Pharmaceutical

Editorial Board Member

Naglaa Shehab β€” Dubai Medical University
Naglaa Shehab
Affiliation Dubai Medical University
Country United Arab Emirates
Scopus ID 26424069600
Documents 446
Citations 494
h-index 13
Subject Area Drug Discovery and Development
Event International Top Pharmaceutical Awards
ORCID 0000-0002-7514-4055

Naglaa Shehab is recognized for her academic and scientific contributions in pharmaceutical sciences, pharmacognosy, medicinal plant research, and drug discovery investigations. Her scholarly activities demonstrate continuous engagement in phytochemical analysis, natural product development, biological activity assessment, and interdisciplinary pharmaceutical research. Through her editorial and academic involvement at Dubai Medical University, she has contributed to advancing research standards and scientific communication within pharmaceutical sciences.[1] Her work reflects sustained participation in pharmacological innovation, natural medicine evaluation, and translational pharmaceutical studies with relevance to both academic and clinical applications.[2]

Abstract

This academic article presents a structured overview of the editorial and scientific profile of Naglaa Shehab within the field of pharmaceutical sciences. The profile highlights her contributions to pharmacognosy, medicinal plant research, phytochemical investigations, drug-herb interaction studies, and pharmaceutical development. Her research activities demonstrate interdisciplinary collaboration across pharmaceutical chemistry, biological evaluation, and natural product therapeutics. The article additionally reviews selected scientific publications, citation indicators, institutional affiliations, and academic contributions associated with pharmaceutical innovation and evidence-based natural medicine investigations.[1]

Keywords

Pharmacognosy, Drug Discovery, Medicinal Plants, Pharmaceutical Sciences, Natural Products, Phytochemical Investigation, Drug Development, Pharmaceutical Research, Herbal Medicine, Biological Activities

Introduction

Research in pharmaceutical sciences increasingly integrates natural product chemistry, biological evaluation, and translational therapeutic development. Naglaa Shehab has contributed to this multidisciplinary area through research involving medicinal plants, phytochemical profiling, anticancer evaluation, antioxidant studies, and pharmaceutical formulations. Her scientific work spans multiple domains including pharmacognosy, pharmaceutical chemistry, and drug interaction investigations. These activities support broader efforts to identify bioactive compounds and therapeutic applications relevant to healthcare and pharmaceutical innovation.[3]

Research Profile

Naglaa Shehab serves within the academic environment of Dubai Medical University and maintains active involvement in pharmaceutical sciences education and research. Her profile reflects long-term experience in pharmacognosy, medicinal plant analysis, extraction methodologies, and phytochemical characterization. Academic responsibilities have included curriculum development, faculty activities, research coordination, and scientific mentoring. Research interests include herbal-drug interactions, biological evaluation of natural compounds, pharmaceutical formulations, and investigation of medicinal plant constituents with potential therapeutic applications.[1]

  • Research specialization in pharmacognosy and natural products
  • Experience in medicinal plant extraction and phytochemical analysis
  • Editorial and academic participation in pharmaceutical sciences
  • Focus on biological activity evaluation and drug development research

Research Contributions

The research contributions associated with Naglaa Shehab include investigations into anticancer activity, antioxidant mechanisms, hepatoprotective effects, pharmaceutical nanocarriers, herbal formulations, and phytotherapeutic interventions. Her work has examined medicinal plant extracts and their applications in pharmaceutical formulations intended for therapeutic evaluation. Several studies have explored cancer-related mechanisms, drug safety, inflammatory modulation, and natural compounds with potential pharmacological significance.[2][4]

  • Development of phytochemical and natural product formulations
  • Evaluation of anticancer and antioxidant activities
  • Research on medicinal plant-derived therapeutic compounds
  • Studies addressing pharmaceutical efficacy and biological mechanisms

Publications

The publication record of Naglaa Shehab primarily focuses on pharmacognosy, medicinal plants, phytochemical investigations, pharmaceutical formulations, and biological activity evaluation of natural compounds. Her studies commonly explore anticancer activity, antioxidant mechanisms, herbal therapeutics, drug-herb interactions, and pharmaceutical applications of plant-derived bioactive substances. Several publications investigate the therapeutic potential of medicinal extracts through experimental and pharmaceutical approaches, particularly in cancer treatment, inflammatory disorders, hepatoprotective activity, and pharmaceutical nanocarrier systems. The research profile also demonstrates continued involvement in interdisciplinary pharmaceutical sciences and evidence-based natural product development.[3][4]

Research Impact

The research profile of Naglaa Shehab demonstrates measurable scholarly engagement through indexed publications, citation activity, and interdisciplinary pharmaceutical investigations. Her scientific output has addressed medicinal chemistry, herbal medicine, oncology-related pharmaceutical research, and biological evaluation of natural compounds. The documented h-index and citation metrics indicate ongoing academic visibility within pharmaceutical and pharmacognosy-related research communities.[1][5]

Award Suitability

Naglaa Shehab demonstrates suitability for recognition within pharmaceutical and biomedical academic platforms due to her contributions to drug discovery, pharmacognosy, medicinal plant investigations, and pharmaceutical sciences education. Her participation in scientific publishing, interdisciplinary collaborations, and research development aligns with the objectives of international pharmaceutical recognition initiatives. The combination of research productivity, editorial engagement, and pharmaceutical innovation supports her relevance to academic award and editorial board recognition programs.[5]

Conclusion

The academic profile of Naglaa Shehab reflects continued engagement in pharmaceutical sciences, medicinal plant investigations, and natural product research. Her scholarly contributions encompass pharmaceutical formulations, phytochemical analysis, biological evaluation, and interdisciplinary healthcare applications. Through editorial participation, scientific publications, and pharmaceutical research activities, she contributes to ongoing developments within drug discovery and pharmaceutical innovation.[1][2]

References

  1. ORCID. (2026). Naglaa Shehab ORCID profile and academic activities. ORCID Registry.https://orcid.org/0000-0002-7514-4055
  2. Elsevier. (n.d.). Scopus author details: Naglaa Shehab, Author ID 26424069600. Scopus.https://www.scopus.com/authid/detail.uri?authorId=26424069600
  3. Khalifa, A., Shehab, N.G., et al. (2026). Development of Phyllanthus emblica Extract-Loaded Niosomes for Cancer Treatment: Formulation and In Vitro Evaluation. Pharmaceuticals.DOI:https://doi.org/10.3390/ph19040582
  4. Bou Malhab, L.J., Shehab, N.G., et al. (2023). Potential Anticancer Properties of Calotropis procera: An Investigation on Breast and Colon Cancer Cells. Heliyon.DOI:https://doi.org/10.1016/j.heliyon.2023.e16706
  5. Anbar, H.S., El Wakil, A., Shehab, N.G., et al. (2024). The wound healing and hypoglycemic activates of date palm (Phoenix dactylifera) leaf extract and saponins in diabetic and normal rats. PLOS ONE.
    DOI: https://doi.org/10.1371/journal.pone.0308879

Walter Manucha | Nanopharmacology | Best Researcher Award

Published on by Top Pharmaceutical

Best Researcher Award

Walter Manucha
National Scientific and Technical Research Council, Argentina
Walter Manucha
Affiliation National Scientific and Technical Research Council
Country Argentina
Scopus ID 57195218813
Documents 2665
Citations 3316
h-index 34
Subject Area Nanopharmacology
Event International Top Pharmaceutical Awards
ORCID 0000-0002-2279-7626

Walter Manucha is a researcher affiliated with the National Scientific and Technical Research Council in Argentina, with academic contributions associated with nanopharmacology, biomedical sciences, and translational therapeutic research. His scholarly profile reflects extensive publication activity, interdisciplinary scientific collaboration, and measurable citation performance within international indexing systems.[1] The recognition associated with the Best Researcher Award acknowledges sustained research productivity, scientific influence, and contributions to pharmaceutical and biomedical advancement within an international academic framework.[2]

Abstract

The Best Researcher Award article documents the academic profile and research standing of Walter Manucha in the field of nanopharmacology and pharmaceutical sciences. The article summarizes publication metrics, scholarly influence, interdisciplinary contributions, and international research visibility indexed through global academic databases.[1] It also evaluates the researcher’s suitability for recognition under the International Top Pharmaceutical Awards framework, emphasizing scientific productivity, citation impact, and contributions to biomedical innovation.[2]

Keywords

Nanopharmacology, Pharmaceutical Sciences, Biomedical Research, Drug Delivery, Translational Medicine, Scopus Metrics, Scientific Impact, Research Excellence, International Awards, Academic Recognition

Introduction

Academic recognition programs in pharmaceutical sciences frequently evaluate candidates using publication performance, citation analysis, interdisciplinary collaboration, and international scientific influence. Walter Manucha’s research activities are associated with nanopharmacology and therapeutic innovation, areas that continue to contribute to modern biomedical and pharmaceutical development.[1] Through indexed scholarly publications and measurable citation metrics, the researcher demonstrates sustained participation in peer-reviewed scientific advancement and international academic communication.[3]

Research Profile

Walter Manucha is affiliated with the National Scientific and Technical Research Council in Argentina and has developed a research profile connected to nanopharmacology, pharmaceutical sciences, and biomedical investigation. The Scopus-indexed profile records substantial publication activity and measurable scholarly visibility through citations and h-index indicators.[1] His academic contributions demonstrate participation in multidisciplinary scientific collaboration and translational research themes relevant to therapeutic sciences and clinical innovation.[4]

  • Institutional affiliation with the National Scientific and Technical Research Council.
  • Research specialization associated with nanopharmacology and biomedical sciences.
  • Scopus-indexed publication and citation visibility.
  • International academic dissemination and interdisciplinary collaboration.

Research Contributions

The researcher’s scientific activities contribute to areas related to drug development, therapeutic mechanisms, biomedical applications, and pharmaceutical innovation. Nanopharmacology represents an emerging interdisciplinary field integrating nanotechnology with pharmacological sciences to improve targeted therapeutic approaches and biomedical efficiency.[4] The research output associated with Walter Manucha reflects scholarly engagement with evolving pharmaceutical technologies and evidence-based biomedical methodologies.[5]

  • Development of interdisciplinary biomedical research frameworks.
  • Contributions to therapeutic and pharmaceutical sciences.
  • Scientific dissemination through indexed journal publications.
  • Participation in internationally recognized research communication platforms.

Publications

The publication record associated with Walter Manucha reflects extensive participation in scholarly communication and indexed scientific literature. Indexed databases identify numerous publications linked to pharmaceutical sciences and biomedical research themes.[1] Publication visibility and citation engagement indicate active dissemination within the international scientific community.[3]

  1. Research articles in nanopharmacology and biomedical sciences.
  2. Peer-reviewed publications indexed in international databases.
  3. Collaborative scientific contributions in pharmaceutical research.
  4. Publications contributing to translational and therapeutic innovation.

Research Impact

Research impact indicators demonstrate measurable academic visibility through citation performance, indexed publications, and h-index evaluation. Citation activity associated with the researcher indicates that published works have contributed to ongoing scientific discussion and scholarly reference within related biomedical domains.[1] The h-index score further reflects sustained research productivity and academic engagement over time.[3]

  • Scopus-indexed visibility and citation accumulation.
  • Sustained publication activity within pharmaceutical sciences.
  • Research dissemination through international scholarly networks.
  • Academic influence reflected through measurable bibliometric indicators.

Award Suitability

The Best Researcher Award recognizes sustained scientific contribution, publication excellence, and measurable academic impact within pharmaceutical and biomedical sciences. Walter Manucha’s documented research metrics, publication record, and interdisciplinary scientific involvement demonstrate alignment with the evaluative principles commonly associated with international academic recognition programs.[2] The researcher’s profile indicates scholarly consistency, international indexing visibility, and participation in evidence-based scientific advancement relevant to nanopharmacology and translational biomedical research.[5]

Conclusion

Walter Manucha’s academic profile reflects sustained scientific productivity, interdisciplinary collaboration, and measurable scholarly visibility within pharmaceutical and biomedical sciences. Through indexed publications, citation performance, and contributions associated with nanopharmacology, the researcher demonstrates continued engagement with internationally recognized scientific research activities.[1] The documented academic metrics and research dissemination support recognition under the Best Researcher Award category within the International Top Pharmaceutical Awards framework.[2]

References

  1. Elsevier. (n.d.). Scopus author details: Walter Manucha, Author ID 57195218813. Scopus.
    https://www.scopus.com/authid/detail.uri?authorId=57195218813
  2. International Top Pharmaceutical Awards. (n.d.). Academic recognition and pharmaceutical research excellence platform.
    https://toppharmaceutical.org/
  3. MartΓ­n Gimenez, V. M., GarcΓ­a Menendez, S., & Manucha, W. (2026). Multi-endogenous nanoformulation for endocannabinoid and hormonal modulation of key signaling pathways in resistant hypertension. Current Pharmaceutical Design.
    https://doi.org/10.2174/0113816128396666250728074858
  4. Reiter, R. J., Sharma, R., Loh, D., Chuffa, L. G. A., Bai, Y., Zuccari, D. A. P. C., Galano, A., & Manucha, W. (2026). Melatonin targets mitochondrial redox homeostasis: Optimizing the intracellular microenvironment. International Journal of Molecular Sciences.
    https://doi.org/10.3390/ijms27104496
  5. Carloni, S., Luchetti, F., Nasoni, M. G., Balduini, W., Manucha, W., & Reiter, R. J. (2026). Melatonin and mitochondrial stress: New insights into age-related neurodegeneration. Neural Regeneration Research.
    https://doi.org/10.4103/NRR.NRR-D-24-01380

lingcong KONG | Drug Discovery and Development | Best Researcher Award

Published on by Top Pharmaceutical

lingcong KONG | Drug Discovery and Development | Best Researcher Award

Prof. lingcong KONG at Jilin Agriculture University, China.

Prof. Lingcong Kong is a dedicated veterinary scientist with a Ph.D. in Preventive Veterinary Medicine from Jilin Agricultural University πŸŽ“. He teaches courses like Veterinary Pharmacology and Animal Toxicology πŸ„ and actively mentors students in national competitions πŸ†. His research focuses on antimicrobial resistance, drug resistance mechanisms, and the development of resistance inhibitors in animal pathogens 🧫🦠. He has led numerous national and provincial projects, holds multiple patents for veterinary vaccines πŸ’‰, and has published extensively in high-impact journals πŸ“š. His work significantly enhances diagnostic tools and contributes to sustainable animal healthcare.

Publication ProfileΒ 

Scopus

Education

Prof. Lingcong Kong began his academic journey at the Inner Mongolia University for Nationalities, where he earned his Bachelor of Veterinary Medicine from September 2006 to July 2010 🐾. He then pursued advanced studies at Jilin Agricultural University, completing a Master’s degree in Basic Veterinary Medicine between 2010 and 2013 πŸ§ͺ. Driven by a deep passion for animal health, he continued at the same institution to earn his Ph.D. in Preventive Veterinary Medicine from September 2013 to July 2016 πŸ”¬. His education laid a strong foundation for his impactful contributions to veterinary science and research.

Experience

Prof. Lingcong Kong is a dedicated educator who teaches undergraduate courses such as “Veterinary Pharmacology”, “Veterinary Pharmacology Experiment”, and “Animal Toxicology” 🐾. At the graduate level, he lectures on “Veterinary Drug Research and Creation”, “Advanced Pharmacology”, and “Veterinary Pharmacology and Toxicology” πŸ’Š. He actively mentors students in scientific competitions, leading them to prestigious honors like the 2022 Internet+ National Award (2nd Prize) πŸ…, Provincial Award (1st Prize) πŸ₯‡, and innovation contests. His guidance also earned him the Outstanding Paper Award πŸ“ and the Dazenong Innovation Guidance Award in 2018 πŸŽ–οΈ, highlighting his commitment to academic excellence and innovation.

Awards

Prof. Lingcong Kong has pioneered breakthroughs in detecting and combating drug-resistant animal pathogens πŸ„πŸ§«. His innovations include PCR-ELISA rapid detection, immunomagnetic bead enrichment, and high-throughput methods for resistance gene testing πŸ§ͺ. He established a pathogenic bacteria resource library πŸ“š and developed functional probiotics to prevent animal diarrhea πŸ’Š. By identifying 8 key resistance inhibitor targets and 6 promising lead compounds, his work has revolutionized lab diagnostics, minimized economic losses in livestock, and enhanced ecological health πŸŒ±πŸ’Ό. His efforts significantly advance animal healthcare and veterinary pharmacology across Jilin Province and beyond.

Research FocusΒ 

Prof. Lingcong Kong focuses on veterinary pharmacology, particularly targeting antimicrobial resistance and infectious diseases in animals πŸ„πŸ¦ . His cutting-edge research includes discovering novel natural inhibitors like coniferaldehyde and protocatechuic aldehyde to combat Staphylococcus aureus πŸ§ͺπŸ”¬. He also explores gene transfer mechanisms, antibiotic degradation pathways, and repurposing small molecules to inhibit bacterial enzymes like KPC-2 πŸ’Š. By studying agents such as C15-bacillomycin D and antibacterial proteins from Bacillus velezensis, he contributes significantly to combatting multidrug-resistant pathogens in animal and environmental health.

Publication Top Notes

  • Discovery of coniferaldehyde as an inhibitor of caseinolytic protease to combat Staphylococcus aureus infections
  • Anti-infective therapy of inhibiting Staphylococcus aureus ClpP by protocatechuic aldehyde
  • Acidifiers promoted antibiotic resistance gene transfer via plasmid conjugation
  • Efficient degradation of tylosin by Kurthia gibsonii TYL-A1: performance, pathway, and genomics study
  • Repurposing tavaborole to combat resistant bacterial infections through competitive inhibition of KPC-2 and metabolic disruption
  • A Novel Protein Demonstrating Antibacterial Activity Against Multidrug-Resistant Escherichia coli Purified from Bacillus velezensis CB6
  • C15-bacillomycin D produced by Bacillus amyloliquefaciens 4-9-2 suppress Fusarium graminearum infection and mycotoxin biosynthesis

Surya Nandan Meena | Drug Discovery and Development | Best Researcher Award

Published on by Top Pharmaceutical

Surya Nandan Meena | Drug Discovery and Development | Best Researcher Award

Dr. Surya Nandan Meena, Savitribai Phule Pune University, India

Dr. Surya Nandan Meena is an accomplished researcher in natural product chemistry with over 7 years of postdoctoral experience. He has authored 16 peer-reviewed publications, 4 books, and 8 book chapters, focusing on anticancer and antidiabetic compound discovery. 🧬 His expertise spans LC-MS/MS, molecular docking, and mammalian cell assays. πŸŽ“ A recipient of prestigious fellowships like the Dr. D.S. Kothari and SERB-DST, he has led international projects, mentored students, and contributed to multidisciplinary science globally. 🌱 Passionate about drug discovery and marine biotechnology, Dr. Meena actively serves on editorial boards and scientific societies worldwide.

Publication Profile

Google Scholar

Education

Dr. Surya Nandan Meena is a dedicated scholar with a robust academic background in biotechnology and agriculture. He earned his Ph.D. in Biotechnology from Goa University, India (Nov 2010 – April 2017), where he conducted extensive research in the field. Prior to that, he completed his M.Sc. in Plant Biotechnology from UAS Dharwad, India (July 2006 – April 2009), further refining his expertise in plant sciences 🌿. His academic journey began with a B.Sc. (Hons) in Agriculture from MPUAT, Udaipur, Rajasthan (July 2002 – June 2006) 🌾, laying a strong foundation for his future contributions to agricultural biotechnology.

Awards

Dr. Surya Nandan Meena has been honored with numerous prestigious awards and research fellowships throughout his academic journey. In 2019, he received the Kothari Postdoctoral Research Fellowship from UGC, India. He earned the Best Research Paper Appreciation Award from Anchrome Pvt. Ltd. in 2018 πŸ“œ. In 2017, he was awarded the National Postdoctoral Fellowship by SERB-DST, India. His dedication was also recognized with the Senior Research Fellowship from DBT in 2013 and the Best Poster Presentation Award in 2012 πŸ§ͺ. Earlier, he secured the Junior Research Fellowship from DBT in 2009 and the JNU CEEB Fellowship in 2006 πŸŽ“.

Experience

Dr. Surya Nandan Meena brings a wealth of professional experience in biotechnology and marine research. Since Nov 2019, he has served as a Postdoctoral Fellow at Pune University, conducting mammalian cell-based assays and characterizing bioactive seaweed compounds 🌊. Earlier, at the National Institute of Oceanography (2017–2019), he surveyed 35+ seaweed species and contributed to multiple publications πŸ“š. As a Senior Research Fellow at ICAR-CCARI (2016–2017), he identified beneficial microbial strains 🌱 and developed plant growth formulations. His roles also included mentoring students, publishing in high-impact journals, and leading interdisciplinary research, reflecting his dedication to scientific innovation and collaboration πŸ‘¨β€πŸ”¬.

Research Focus

Dr. Surya Nandan Meena’s research centers on natural product chemistry, sustainable bioresource utilization, and drug discovery. His work bridges the gap between marine and terrestrial natural compounds for therapeutic applications, especially targeting antidiabetic, antioxidant, and anticancer properties. With notable contributions in biocatalysis, phytochemistry, and biosynthetic pathways, Dr. Meena emphasizes green, solvent-free synthesis and eco-friendly resource management. He actively explores seaweed farming, plant-based compounds, and essential oils as potent sources for novel bioactives. His multidisciplinary approach contributes significantly to natural compound-based drug development and sustainable healthcare innovation.

Publication Top Notes

Natural resources conservation and advances for sustainability

Graphite catalyzed solvent free synthesis of dihydropyrimidin-2 (1H)-ones/thiones and their antidiabetic activity

Seaweed Farming: A Perspective of Sustainable Agriculture and Socio-economic Development

Advances in Biological Science Research: A Practical Approach

Biosynthesis of vanillic acid by Ochrobactrum anthropi and its applications

Ξ±-Glucosidase inhibition activity and in silico study of 2-(benzo [d][1, 3] dioxol-5-yl)-4H-chromen-4-one, a synthetic derivative of flavone

Quick Identification of Piperidine Alkaloid from Roots ofΒ Grewia nervosaΒ and Their Glucosidase Inhibitory Activity

Antioxidant and antiglycemic properties of macroalgae, an underutilized blue economy bioresource in India

Evaluation of silver-doped indium oxide nanoparticles as in vitro Ξ±-amylase and Ξ±-glucosidase inhibitors

New horizons in natural compound research

Biodegradation of seafood waste by seaweed-associated bacteria and application of seafood waste for ethanol production

Mario Leporace | Personalized Medicine | Best Innovation Award

Published on by Top Pharmaceutical

Mario Leporace | Personalized Medicine | Best Innovation Award

Prof. Dr. Mario Leporace, Hospital and University, Italy

Prof. Dr. Mario Leporace is a distinguished Clinical Radiologist at the Department of Nuclear Medicine and Theragnostics, β€œMariano Santo” Hospital, Cosenza, Italy. With expertise in oncologic imaging, hybrid and molecular imaging, and cardiovascular radiology, he is renowned for his advanced diagnostic work using X-ray, CT, MRI, PET/CT, and SPECT/CT. He holds a Master’s in Interventional Oncology and has contributed to over 15 peer-reviewed publications. His professional journey spans top institutions in Rome and Cosenza, marking a career dedicated to innovation in radiology and nuclear medicine.

Publication Profile

Scopus

Education

Prof. Dr. Mario Leporace πŸŽ“ is a distinguished expert in interventional oncology and radiology. In 2022, he earned a Master’s Degree in Interventional Oncology from Fondazione Policlinico Universitario A. Gemelli IRCCS in Rome, with a thesis on thermal ablation of bone metastases πŸ”₯🦴. From 2001 to 2005, he completed his post-graduate certification in Radiology at the University of Rome β€œTor Vergata” πŸ₯, graduating cum laude with a thesis on hybrid imaging πŸ§ πŸ“Έ. He also obtained his Degree in Medicine and Surgery from the same university (1995–2001), graduating with top honors and a thesis in vascular imaging πŸ«€πŸ§¬.

Experience

Prof. Dr. Mario Leporace 🩺 has an extensive career in radiology and nuclear medicine, showcasing over two decades of dedicated medical service. Since October 2017, he has been serving in the Department of Nuclear Medicine and Theragnostics at β€œMariano Santo” Hospital in Cosenza, Italy βš›οΈπŸ₯. From May 2016 to September 2017, he worked at the Department of Radiology, β€œAnnunziata” Hospital 🏨. Earlier, from March 2006 to April 2016, he contributed to the European Hospital in Rome, and concurrently, from November 2005 to April 2016, served at the Aurelia Hospital in Rome πŸ›οΈπŸ”¬, strengthening his clinical expertise across institutions.

Research Focus

Prof. Dr. Mario Leporace focuses his research on Thermal Ablation with Magnetic Resonance-guided Focused Ultrasound Surgery (MRgFUS) πŸ”¬πŸ§ . His work bridges medical physics and oncological applications, exploring non-invasive treatments that use focused ultrasound energy to thermally ablate tumors with MRI precision guidance 🎯. This technique offers cutting-edge therapeutic possibilities in fields such as oncology, neurology, and women’s health πŸ§¬πŸ’‘. Prof. Leporace’s contributions advance both the clinical outcomes and technological innovation of MRgFUS, making him a key figure in image-guided therapy, minimally invasive surgery, and cancer treatment research .

Publication Top Notes

The Thermal Ablation with MRgFUS: From Physics to Oncological Applications

Jameel Al-Tamimi | Biopharmaceutics | Best Researcher Award

Published on by Top Pharmaceutical

Jameel Al-Tamimi | Biopharmaceutics | Best Researcher Award

Dr. Jameel Al-Tamimi, King Saud University, Saudi Arabia

Dr. Jameel Al-Tamimi is a distinguished researcher with a Ph.D. in Immunogenetics from King Saud University, Riyadh, Saudi Arabia. His research focuses on immunology, particularly the role of Killer Immunoglobulin-like Receptors (KIRs) in leukemia. He has expertise in molecular techniques, immunology, and forensic entomology. Dr. Al-Tamimi has published numerous research articles and has contributed to various academic committees. His teaching experience spans courses in molecular biology, human physiology, and medical entomology.

Publication Profile

Google Scholar

Education

Dr. Jameel Al-Tamimi πŸŽ“ is a distinguished researcher with a Ph.D. in Immunogenetics (Excellent 4.9/5) from King Saud University, where his thesis explored the Role of Killer Immunoglobulin-like Receptors (KIRs) with HLA Ligands in Saudi Leukemia Patients 🧬. He also holds an M.Sc. in Entomology and Parasitology (Excellent 4.9/5), investigating the anti-inflammatory effects of Pachycondyla sennaarensis (Samsum Ant) venom in male albino rats 🐜πŸ§ͺ. Dr. Al-Tamimi earned his B.Sc. in Biology (Very Good 89.9/100) from Thamar University, Yemen, with research focused on physiological changes in viral hepatitis (HbsAg and HCV) patients at Thamar Hospital 🧫🦠.

Experience

Dr. Jameel Al-Tamimi πŸ§‘β€πŸ”¬ brings a wealth of academic and research experience. Since 2023, he has served on the Scientific Committee for the Researcher Support Program (RSPD) and Research Groups Program (RGP) at the Deanship of Scientific Research πŸ“š. At King Saud University, he contributed to key committees, including labs, academic accreditation, exams, and graduate studies πŸ›οΈ. He supervised both the endocrinology and immunology laboratories πŸ§ͺ and mentored undergraduate and master’s students πŸŽ“. Skilled in handling rats, mice, and insects πŸ­πŸ¦—, Dr. Al-Tamimi is also proficient in advanced molecular biology, immunology, and physiology techniques πŸ§¬πŸ”¬.

Awards

Dr. Jameel Al-Tamimi πŸŽ“ has been recognized for his academic excellence with several prestigious awards. In 2015, he received an acknowledgment certificate from the Chairman of the Center of Excellence in the Development of Science and Mathematics Education at King Saud University πŸ…, highlighting his contribution to scientific advancement. Earlier, in 2013, he was honored with a Certificate of Appreciation (General Prize) during the first Graduate Student Annual Scientific Meeting at KSU πŸ“œπŸŽ‰. These achievements reflect his dedication to academic excellence, innovation in research, and commitment to the scientific community πŸŒŸπŸ“š.

Research Focus

Dr. Jameel Al-Tamimi is a multidisciplinary biomedical researcher whose primary focus lies in oxidative stress, wound healing, diabetes, and nanoparticle therapeutics. His work spans nanomedicine, immunomodulation, and natural product pharmacology, particularly in evaluating the biological activities of camel milk peptides, selenium and zinc oxide nanoparticles, and bioactive plant extracts. Dr. Al-Tamimi’s studies contribute significantly to redox biology, diabetic complications, and biofabrication of therapeutic agents, offering innovative strategies for combating chronic diseases and enhancing healing processes. πŸ§«πŸ’ŠπŸ« His collaborative work reflects a strong emphasis on toxicology, regenerative medicine, and bio-nanotechnology.

Publication Top Notes

Camel milk peptide improves wound healing in diabetic rats by orchestrating the redox status and immune response

Wound healing of different molecular weight of hyaluronan; in-vivo study‏

Folic acid and melatonin mitigate diabetic nephropathy in rats via inhibition of oxidative stress‏

Synthesis, structural characterization of silver (I)-NHC complexes and their antimicrobial, antioxidant and antitumor activities‏

Potential effects of the combination of nicotinamide, vitamin B2 and vitamin C on oxidative-mediated hepatotoxicity induced by thioacetamide‏

Efficacy of a Methanolic Extract ofΒ Adansonia digitataΒ Leaf in Alleviating Hyperglycemia, Hyperlipidemia, and Oxidative Stress of Diabetic Rats‏

Antioxidant Bioactivity of Samsum Ant (Pachycondyla sennaarensis) Venom Protects against CCL4‐Induced Nephrotoxicity in Mice‏

Biofabrication of Zinc Oxide Nanoparticle fromΒ Ochradenus baccatusΒ Leaves: Broad‐Spectrum Antibiofilm Activity, Protein Binding Studies, andΒ In VivoΒ Toxicity …‏

Xia Xiao | Pharmacodynamics | Best Researcher Award

Published on by Top Pharmaceutical

Xia Xiao | Pharmacodynamics | Best Researcher Award

Assoc. Prof. Dr. Xia Xiao, Yangzhou University, China

Assoc. Prof. Dr. Xia Xiao is a distinguished researcher in veterinary microbiology at Yangzhou University. He earned his Ph.D. in Veterinary Science from South China Agricultural University (2015) πŸŽ“, specializing in bacteriophage-mediated antibiotic resistance. His research focuses on antimicrobial pharmacokinetics, novel antimicrobial agents, and bacterial resistance mechanisms πŸ¦ πŸ’Š. A former visiting scholar at UCLA (2018-2019), Dr. Xiao has published extensively in high-impact journals πŸ“š. His work contributes to the rational use of antibiotics and combating multidrug resistance, advancing veterinary and human medicine alike. πŸ†πŸ”

Publication Profile

Scopus

Education

Assoc. Prof. Dr. Xia Xiao is a leading veterinary microbiologist at Yangzhou University. He earned his Ph.D. in Veterinary Science from South China Agricultural University (2015) πŸŽ“, specializing in bacteriophage-mediated antibiotic resistance. As a former visiting scholar at UCLA (2018-2019) 🌍, his research focuses on antimicrobial pharmacokinetics, novel antimicrobial agents, and bacterial resistance mechanisms πŸ¦ πŸ’Š. Since 2020, he has been an Associate Professor, contributing to advancements in antibiotic utilization and resistance control. His work plays a crucial role in improving both veterinary and human medicine. πŸ“š

Experience

Assoc. Prof. Dr. Xia Xiao is a veterinary microbiologist at Yangzhou University, specializing in antimicrobial resistance πŸ¦ πŸ’Š. He earned his Ph.D. from South China Agricultural University (2015) πŸŽ“, focusing on bacteriophage-mediated antibiotic resistance. As a Visiting Scholar at UCLA (2018-2019) 🌍, he expanded his research through international collaborations, enhancing his contributions to the global scientific community πŸ”¬πŸ€. His work explores antibiotic pharmacokinetics, novel antimicrobial agents, and bacterial resistance strategies. Since 2020, he has been an Associate Professor, making impactful strides in veterinary and human medicine. πŸ“šπŸ†

Focus Areas

Assoc. Prof. Dr. Xia Xiao is a veterinary microbiologist at Yangzhou University, specializing in antimicrobial resistance and antibiotic optimization πŸ’ŠπŸ“Š. He earned his Ph.D. from South China Agricultural University (2015) πŸŽ“ and later expanded his research through international collaboration as a Visiting Scholar at UCLA (2018-2019) 🌍. His work focuses on pharmacokinetics-based antibiotic use, novel antimicrobial development, and strategies to combat bacterial resistance πŸ₯βš•οΈ. His groundbreaking research on bacteriophage-mediated resistance transmission addresses global health challenges, making significant contributions to veterinary and medical microbiology. πŸ“šπŸ†

Research Focus

Assoc. Prof. Dr. Xia Xiao’s research primarily focuses on antimicrobial resistance (AMR) πŸ¦ πŸ’Š, pharmacokinetics/pharmacodynamics (PK/PD) modeling πŸ“ŠπŸ§ͺ, and bacterial resistance mechanisms πŸ”¬πŸ§«. Her work explores the role of resistance genes, such as mcr-1, blaNDM-5, and tet(X4), in multidrug-resistant pathogens, including Klebsiella pneumoniae and Escherichia coli. She investigates novel strategies to combat AMR, including using natural compounds 🌿, repurposed drugs πŸ’‘, and PK/PD-based optimization πŸ“‰πŸ“ˆ. Her research has significant implications for developing effective treatments against drug-resistant infections in both humans and animals πŸ₯🐾.

Publication Top Notes

DNA Polymerase IV dinB Favors the Adaptive Fitness of mcr-carrying Bacteria Through a Negative Feedback Regulatory Mechanism

Acetylshikonin Derived From Arnebia euchroma (Royle) Johnst Kills Multidrug-Resistant Gram-Positive Pathogens In Vitro and In Vivo

Acetylshikonin reduces the spread of antibiotic resistance via plasmid conjugation

The Food Additive Benzaldehyde Confers a Broad Antibiotic Tolerance by Modulating Bacterial Metabolism and Inhibiting the Formation of Bacterial Flagella

Gramine sensitizes Klebsiella pneumoniae to tigecycline killing

Characterization of a cfr-bearing integrative and conjugative element in Proteus cibarius coharbouring tet(X6) on the chromosome

KYU SHIK MUN | Personalized Medicine | Best Researcher Award

Published on by Top Pharmaceutical

KYU SHIK MUN | Personalized Medicine | Best Researcher Award

Assist. Prof. Dr. KYU SHIK MUN, Cedars-Sinai Medical Center, United States

Assist. Prof. Dr. Kyu Shik Mun is a distinguished researcher in cystic fibrosis (CF) and biomedical engineering 🧬. As a Principal Investigator and Co-Director, he has led groundbreaking projects on CF-related diabetes, organ-on-a-chip models, and personalized CF therapy πŸ₯. His work, funded by organizations like the Cystic Fibrosis Foundation and Vertex Pharmaceuticals, has yielded significant patents and high-impact publications πŸ“‘. With 733 citations, an h-index of 10, and an i10-index of 10, Dr. Mun continues to drive innovations in CF research, bridging biomedical science and translational medicine πŸ”¬.

Publication Profile

Google Scholar

Professional Background

Assist. Prof. Dr. Kyu Shik Mun earned his Ph.D. in the Materials Science and Engineering Program at the University of Cincinnati πŸŽ“. In 2016, he joined the Cystic Fibrosis Research Center at Cincinnati Children’s Hospital, where he pioneered a microfluidic-based organ-on-chip program from scratch πŸ₯🧬. His groundbreaking research focused on studying cystic fibrosis and related disorders. In 2021, he was promoted to Assistant Professor at Cedars-Sinai πŸ†, where he continues to advance in vitro cell culture models using organ-on-chip technology and 3D bioprinting πŸ–¨οΈπŸ”¬, contributing to innovative solutions in biomedical research and personalized medicine.

Awards

Assist. Prof. Dr. Kyu Shik Mun has received numerous prestigious honors and awards throughout his academic and professional journey πŸŽ–οΈ. He was awarded multiple Outstanding Grade Scholarships at Gangneung National University πŸ… (2000–2009) and recognized for excellence with department and presidential awards πŸ†. His achievements include a scholarship from the Korean Broadcasting System πŸ“Ί and the Korea Research Foundation 🌏. During his Ph.D. at the University of Cincinnati, he earned a University Graduate Scholarship πŸŽ“ (2010–2014). His research has been recognized by the American Gastroenterological Association and the Cystic Fibrosis Foundation 🧬, receiving multiple Best Abstract and Early Career Investigator awards (2017–2024) πŸ₯‡.

ExperienceΒ 

Assist. Prof. Dr. Kyu Shik Mun has been actively involved in non-clinical teaching, contributing to journal clubs and lab mentoring πŸ“šπŸŽ€. He has delivered key presentations on organ-on-a-chip technology 🧬, including talks at Cincinnati Children’s Hospital (2020) and Cedars-Sinai (2021) πŸ₯. His mentorship spans postdoctoral fellows, research associates, and Ph.D. students, guiding projects in 3D bioprinting πŸ–¨οΈ and patient-derived lung-on-a-chip models 🌬️. Since 2016, he has mentored 15 summer and rotation studentsβ€”including high school, college, Ph.D., and MD candidatesβ€”on fabricating organ-on-a-chips and culturing cells, fostering the next generation of biomedical researchers πŸ”¬.

Research Focus

Assist. Prof. Dr. Kyu Shik Mun’s research primarily focuses on nanotechnology πŸ§ͺ, biosensors 🧫, and biomedical engineering πŸ₯. His work spans optical interferometric biosensors for label-free detection, organ-on-a-chip models for diseases like cystic fibrosis 🫁, and TiOβ‚‚ nanotube arrays for applications in solar cells β˜€οΈ and photocatalysis. He also explores drug discovery πŸ’Š by targeting molecular pathways in cystic fibrosis and related disorders. His interdisciplinary research integrates materials science πŸ—οΈ, biophysics βš›οΈ, and microfluidics πŸ”¬ to develop innovative medical technologies, aiming to advance precision medicine 🎯 and renewable energy solutions 🌱.

Publication Top Notes

A Stable, Label-free Optical Interferometric Biosensor Based on TiO2Β Nanotube Arrays

Patient-derived pancreas-on-a-chip to model cystic fibrosis-related disorders

Guided construction of single cell reference for human and mouse lung

Targeting the pregnane X receptor using microbial metabolite mimicry

Personalized medicine in CF: from modulator development to therapy for cystic fibrosis patients with rare CFTR mutations

Surface passivation of highly ordered TiO2 nanotube arrays and application to dye-sensitized solar cells using the concept of isoelectric point

Targeting DNAJB9, a novel ER luminal co-chaperone, to rescue Ξ”F508-CFTR

Guanylate cyclase 2C agonism corrects CFTR mutants

Cystic Fibrosis Human Organs-on-a-Chip

Johan Alexander Villada Ramos | Drug Discovery and Development | Best Researcher Award

Published on by Top Pharmaceutical

Johan Alexander Villada Ramos | Drug Discovery and Development | Best Researcher Award

Prof. Johan Alexander Villada Ramos, Universidad del QuindΓ­o, Colombia

Johan Alexander Villada Ramos is a Ph.D. candidate in Sciences at Universidad del QuindΓ­o, specializing in natural alternatives to synthetic pesticides 🌱🦠. He holds a Master’s in Biomedical Sciences, earning a meritorious distinction πŸ…, and a Biology degree. His research spans bioactive plant compounds, cancer prevention, and lipid metabolism. As a university lecturer πŸ“š, he teaches molecular biology and biochemistry. With multiple research projects, publications, and awards, including the Carlos Corredor Pereira National Award in Biomedical Sciences (2024) πŸ†, Johan is a dedicated scientist pushing the boundaries of biotechnology and microbiology.

Publication Profile

Orcid

Education

Prof. Johan Alexander Villada Ramos πŸŽ“ is a doctoral student in Sciences at the Universidad del QuindΓ­o, focusing on the bioactivity of free and microencapsulated Tagetes erecta L. 🌿 as an alternative to synthetic pesticides against the avocado weevil Heilipus lauri πŸ₯‘. He earned a Master’s in Biomedical Sciences (2018–2022) with meritorious distinction πŸ…, researching the effects of Passiflora edulis extract on lipid metabolism enzymes in human colorectal adenocarcinoma cells. His Biology degree (2013–2018) involved evaluating the antibacterial activity of Tagetes patula L. against Ralstonia solanacearum. Additionally, he trained in microbiology and biotechnology lab preparation at SENA (2017–2018) πŸ”¬.

Professional Achievements

Prof. Johan Alexander Villada Ramos πŸŽ“ has made significant contributions to biomedical and biological research. He earned a meritorious distinction πŸ… for his master’s research on Passiflora edulis 🍊 and its effects on lipid metabolism in colorectal cancer cells. Holding a Biology degree πŸ”¬, his studies focused on the antimicrobial activity of plant extracts against pathogens. He has been actively involved in high-impact research projects πŸ“š at prestigious institutions, including Pontificia Universidad Javeriana and Universidad del QuindΓ­o. His work continues to advance natural alternatives 🌱 in disease management, reinforcing his dedication to scientific discovery and innovation.

Leadership in Academia

Prof. Johan Alexander Villada Ramos πŸŽ“ is a dedicated academic leader, serving as a lecturer πŸ“– in molecular biology, biochemistry, and microbiology πŸ”¬ at Universidad del QuindΓ­o. Passionate about education, he actively contributes to curriculum development 🏫, ensuring that students receive up-to-date and high-quality training. Additionally, he plays a key role in laboratory training πŸ§ͺ, equipping future scientists with essential research skills. His commitment to fostering scientific knowledge and practical expertise strengthens the university’s academic foundation, inspiring students to excel in the fields of biotechnology, microbiology, and biomedical sciences. πŸš€

Research Focus

Prof. Johan Alexander Villada Ramos specializes in natural product chemistry, biochemistry, and phytopharmacology, with a strong focus on the antioxidant, antibacterial, and anticancer properties of plant extracts. His research explores bioactive compounds from medicinal plants, such as Coffea arabica β˜•, Passiflora edulis πŸƒ, and Tagetes patula 🌼, investigating their effects on oxidative stress, protein oxidation, and bacterial inhibition 🦠. His studies contribute to pharmaceutical development, food science, and biomedicine, aiming to harness plant-derived compounds for disease prevention and therapeutic applications. πŸ₯

Publication Top Notes

Potencial antioxidante del extracto de hoja de Coffea arabica sobre la lipoperoxidaciΓ³n y oxidaciΓ³n proteica en un modelo de mΓΊsculo bovino

Identification of potential bioactive compounds of Passiflora edulis leaf extract against colon adenocarcinoma cells

Evaluation of antibacterial activity of extract and essential oil of Tagetes patula L. in vitro against Ralstonia solanacearum biovar 2

SON DINH PHONG | Gene Therapy | Best Researcher Award

Published on by Top Pharmaceutical

SON DINH PHONG | Gene Therapy | Best Researcher Award

Dr SON DINH PHONG, DUYTAN UNIVERSITY, Vietnam

Dr. Dinh Phong Son is a dedicated researcher in molecular medicine at Duy Tan University, Vietnam. With a Ph.D. from Guangxi Medical University, China, and a background in laboratory medicine from Hue University of Medicine and Pharmacy, his research focuses on molecular biomarkers for early disease detection πŸ§ͺπŸ”¬. He explores the LncRNA/CircRNA/miRNA/gene/protein-drug interaction network and gene-editing techniques like CRISPR/Cas9 for targeted therapy. His work on cardiovascular disease and cancer diagnostics has been published in prestigious journals πŸ“šπŸ§‘β€πŸ”¬. Passionate about advancing molecular biology, he aspires to contribute to innovative breakthroughs in disease research.

Publication Profile

orcid

Education

Dr. Dinh Phong Son πŸŽ“ holds a degree in Laboratory Medicine Technique from Hue University of Medicine and Pharmacy, Vietnam, and a Ph.D. in Molecular Medicine from Guangxi Medical University, China. 🧬 His expertise lies in molecular biology, with a strong focus on disease biomarkers and gene-targeted therapies. πŸ₯πŸ”¬ With a solid academic foundation, he has contributed significantly to scientific advancements, particularly in precision medicine and diagnostics. His research aims to enhance medical treatments by identifying key genetic markers, paving the way for innovative therapeutic approaches. 🌍✨ Dr. Son’s dedication to science continues to drive breakthroughs in healthcare. πŸ’‘πŸ‘¨β€βš•οΈ

Research and Innovations

Dr. Son Dinh Phong πŸ”¬ is deeply engaged in advancing molecular biology through next-generation sequencing and online medical databases. His primary focus is identifying potential biomarkers for early disease detection, including diabetes, cardiovascular diseases, stroke, and cancer. 🧬🩺 His research also explores gene-targeted therapies, utilizing CRISPR/Cas9 for gene editing, overexpression, and silencing. πŸ₯ His studies on LncRNA/CircRNA/miRNA/gene/protein-drug interaction networks provide a foundation for future medical breakthroughs. πŸ“Šβœ¨ Committed to innovation, Dr. Son’s ongoing work (2023-2025) aims to drive scientific progress, hoping for greater support to expand molecular biology research worldwide. πŸŒπŸ’‘

Research Contributions

Dr. Son Dinh Phong πŸ”¬ is highly proficient in advanced molecular biology techniques, including PCR, qPCR, and sequencing analysis πŸ§ͺ🧬. He specializes in CRISPR/Cas9 genome editing, RNA silencing, and overexpression assays, contributing to groundbreaking gene therapy research. πŸ₯ His expertise also includes cell culture, western blotting, and fluorescence in situ hybridization, essential for studying gene expression and protein interactions. πŸ”πŸ§« Additionally, he excels in bioinformatics and molecular docking simulations, enabling in-depth analysis of gene interactions and drug responses. πŸ’»πŸ’Š With a strong foundation in computational biology, Dr. Son continues to drive innovation in precision medicine and molecular diagnostics. πŸš€βœ¨

Editorial Appointments

Dr. Son Dinh Phong πŸŒπŸ”¬ actively contributes to the global scientific community through his extensive research and publications. While specific editorial roles, consultancy projects, or industry collaborations may not be listed, his scholarly work reflects deep engagement in molecular biology and precision medicine. πŸ§¬πŸ“– His ORCID profile further validates his impactful contributions, showcasing his dedication to advancing medical research. πŸ₯✨ Through collaborations and scientific discourse, Dr. Son continues to push the boundaries of innovation, striving to enhance disease diagnostics and therapeutic strategies. His commitment to research ensures lasting contributions to the ever-evolving field of molecular medicine. πŸ’‘πŸš€

Research Focus

Dr. Son Dinh Phong’s research primarily focuses on cardiovascular diseases πŸ«€, non-coding RNAs 🧬, and bioinformatics-driven biomarker discovery πŸ–₯️. His work explores circular RNAs (circRNAs) and microRNAs (miRNAs) in coronary heart disease (CHD) πŸ₯, revealing their role as competing endogenous RNAs (ceRNAs) in gene regulation. Additionally, he investigates serum miRNAs as potential diagnostic biomarkers for various cancers πŸŽ—οΈ and employs computational approaches πŸ”¬ to identify key regulatory networks in diseases like latent tuberculosis 🦠. His studies integrate molecular biology, genomics, and systems biology to advance precision medicine 🎯 and therapeutic innovations πŸ’Š for complex diseases.

Publication Top Notes

Identification and assessment of hub genes and miRNAs coregulatory associated with immune infiltrations and drug interactions in latent tuberculosis based on MicroarrayData analysis, molecular docking, and dynamic simulation

Hsa_circRNA_0000284 acts as a ceRNA to participate in coronary heart disease progression by sponging miRNA-338-3p via regulating the expression of ETS1

Potential diagnostic value of serum microRNAs for 19 cancer types: a meta-analysis of bioinformatics data

Identification of hsa_circ_0001445 of a novel circRNA-miRNA-mRNA regulatory network as potential biomarker for coronary heart disease

Construction of miRNAs and gene expression profiles associated with ischemic cardiomyopathy: Bioinformatics analysis